Trial Profile
CLINICAL PHASE 2 MULTICENTER TRIAL OF PF-00299804 IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2021
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Pfizer
- 06 Jun 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 06 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Nov 2011 Planned End Date changed from 1 Jun 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.